505 Coast Boulevard South
Suite 307
La Jolla, CA 92037
United States
858-952-5500
https://www.calcimedica.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. A. Rachel Leheny Ph.D. | CEO & Director | 852.84k | N/D | 1963 |
Mr. Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board | 757.4k | N/D | 1964 |
Dr. Kenneth A. Stauderman Ph.D. | Co-Founder & Chief Scientific Officer | 615.59k | N/D | 1953 |
Mr. Michael J. Dunn M.B.A., MBA | President & COO | N/D | N/D | 1956 |
Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor | N/D | N/D | N/D |
Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor | N/D | N/D | N/D |
Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor | N/D | N/D | N/D |
Mr. Daniel E. Geffken M.B.A. | Interim Chief Financial Officer | N/D | N/D | 1957 |
Cindy Reiedenberg | Accountant | N/D | N/D | N/D |
Mr. John M. Dunn J.D. | General Counsel | N/D | N/D | 1952 |
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
La calificación ISS Governance QuickScore de CalciMedica, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 10; Junta: 8; Derechos del accionista: 8; Compensación: 9.